Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:

interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC

clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
Clinical Trials Information System (CTIS).

The EU Clinical Trials Register currently displays 44380 clinical trials with a EudraCT protocol, of which 7392 are clinical trials conducted with subjects less than 18 years old. The register also displays information on 18700 older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).

Examples: Cancer AND drug name. Pneumonia AND sponsor name.
How to search [pdf]

Advanced Search:

Search tools

Select Country:	Select Age Range:
Select Trial Status:	Select Trial Phase:
Select Gender:
Select Date Range: to
Select Rare Disease:
IMP with orphan designation in the indication
Orphan Designation Number:
Results Status:
Clear advanced search filters

Trials with a EudraCT protocol (44,380)
Paediatric studies in scope of Art45 of the Paediatric Regulation (0)

44,380 result(s) found. Displaying page 1,777 of 2,219.

EudraCT Number: 2021-000398-10

Sponsor Protocol Number: EFC16133

Start Date*: 2022-04-19

Sponsor Name:Sanofi-aventis recherche & développement

Full Title: A randomized, multicenter, double-blind, Phase 3 study of amcenestrant (SAR439859) versus tamoxifen for the treatment of patients with hormone receptor-positive, human epidermal growth factor 2-neg...

Medical condition: Breast cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10006187	Breast cancer	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Completed) HU (Prematurely Ended) EE (Prematurely Ended) BE (Prematurely Ended) PT (Prematurely Ended) DK (Prematurely Ended) IT (Prematurely Ended) ES (Prematurely Ended)

Trial results: View results

EudraCT Number: 2019-002361-35	Sponsor Protocol Number: Lidocain1	Start Date*: 2020-05-06
Sponsor Name:region Skåne
Full Title: Intavenous Lidocain and postoperative recovery after liver surgery- a randomized double blinded trial
Medical condition: Patients with liver tumours that have liver surgery performed
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: SE (Trial now transitioned)
Trial results: (No results available)

EudraCT Number: 2020-005642-42

Sponsor Protocol Number: KRT-232-114

Start Date*: 2021-05-04

Sponsor Name:Kartos Therapeutics, Inc.

Full Title: An Open-Label, Multicenter, Phase 2 Study Assessing the Safety and Efficacy of KRT-232 or TL-895 in Janus-associated Kinase Inhibitor Treatment-Naïve Myelofibrosis

Medical condition: Primary, post-polycythemia vera (PV), or post-essential thrombocythemia (ET) myelofibrosis (MF), who are treatment naïve to any JAK inhibitor.

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.1	100000004864	10074691	Post polycythaemia vera myelofibrosis	LLT
	21.0	100000004864	10074692	Post essential thrombocythaemia myelofibrosis	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: PL (Completed) BG (Completed)

Trial results: (No results available)

EudraCT Number: 2021-003410-39

Sponsor Protocol Number: D8242C00001

Start Date*: 2023-01-19

Sponsor Name:AstraZeneca AB

Full Title: A Modular Phase I/II, Open-label, Dose Escalation and Expansion, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AZD0466 as Monotherapy or in Com...

Medical condition: Advanced Non-Hodgkin Lymphoma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.1	100000004864	10025315	Lymphoma malignant	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: ES (Prematurely Ended) FR (Completed) IT (Prematurely Ended) PT (Prematurely Ended)

Trial results: View results

EudraCT Number: 2021-003879-34

Sponsor Protocol Number: ROCK-PD-0000-LIN-0075-I

Start Date*: 2023-02-07

Sponsor Name:Klinikum rechts der Isar der Technischen Universität München

Full Title: Safety, Tolerability and Symptomatic Efficacy of the ROCK-Inhibitor Fasudil in Patients with Parkinson's Disease (ROCK-PD)

Medical condition: Idiopathic Parkinson´s Disease

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	10029205 - Nervous system disorders	10061536	Parkinson's disease	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2019-001723-12	Sponsor Protocol Number: ARIVA_venous	Start Date*: 2020-05-28
Sponsor Name:Universitätsspital Zürich, Klinik für Angiologie
Full Title: Aspirin® plus rivaroxaban versus rivaroxaban alone for the prevention of venous stent thrombosis in patients with post-thrombotic syndrome
Medical condition: Post-thrombotic syndrome
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: AT (Prematurely Ended) DE (Prematurely Ended)
Trial results: (No results available)

EudraCT Number: 2020-003445-11

Sponsor Protocol Number: PHA022121-C201

Start Date*: 2020-12-18

Sponsor Name:Pharvaris Netherlands BV

Full Title: A Phase II, double-blind, placebo-controlled, Randomized, cross-over, dose-ranging study of oral PHA-022121 for Acute treatment of angioedema attacks in Patients with hereditary angioedema due to C...

Medical condition: Hereditary angioedema attacks caused by Type 1 and 2 C1-Inhibitor Deficiency

Disease:	Version	SOC Term	Classification Code	Term	Level
	23.1	10010331 - Congenital, familial and genetic disorders	10019860	Hereditary angioedema	PT
	21.0	10010331 - Congenital, familial and genetic disorders	10080956	Hereditary angioedema type I	LLT
	21.0	10010331 - Congenital, familial and genetic disorders	10080957	Hereditary angioedema C1 inhibitor deficiency	LLT
	21.0	10010331 - Congenital, familial and genetic disorders	10080960	Hereditary angioedema type II	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Completed) ES (Completed) HU (Completed) NL (Completed) PL (Completed) DE (Completed) CZ (Completed) BG (Completed) IT (Completed)

Trial results: View results

EudraCT Number: 2021-004276-33

Sponsor Protocol Number: ATA-001-FKRP

Start Date*: 2022-02-11

Sponsor Name:Atamyo Therapeutics

Full Title: A phase 1-2 multicenter study (2 stages) to evaluate the safety and efficacy of intravenous GNT0006, adeno-associated viral vector carrying the FKRP gene, in patients with FKRP-related limb-girdle ...

Medical condition: FKRP-related limb-girdle muscular dystrophy (LGMD R9)

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	10010331 - Congenital, familial and genetic disorders	10028356	Muscular dystrophy	PT

Population Age: Adolescents, Under 18, Adults, Elderly

Gender: Male, Female

Trial protocol: DK (Trial now transitioned) FR (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2021-005136-34

Sponsor Protocol Number: THIO101

Start Date*: 2022-11-16

Sponsor Name:MAIA Biotechnology, Inc.

Full Title: A Multicenter, Open-Label, Dose-Finding, Phase 2 Study Evaluating THIO Sequenced with Cemiplimab (LIBTAYO®) in Subjects with Advanced Non-Small Cell Lung Cancer (NSCLC)

Medical condition: Non-Small Cell Lung Cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10061873	Non-small cell lung cancer	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029519	Non-small cell lung cancer stage III	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029522	Non-small cell lung cancer stage IV	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: BG (Trial now transitioned) PL (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2021-001855-15

Sponsor Protocol Number: QBGJ398-203

Start Date*: 2022-02-02

Sponsor Name:QED Therapeutics, Inc.

Full Title: Phase 2, Open-Label, Long-Term, Extension (OLE) Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children with Achondroplasia: PROPEL OLE

Medical condition: Achondroplasia in Children

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	100000004850	10000452	Achondroplasia	LLT

Population Age: Children, Adolescents, Under 18

Gender: Male, Female

Trial protocol: ES (Ongoing) FR (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2016-004575-49	Sponsor Protocol Number: FFCD-1603	Start Date*: 2017-07-11
Sponsor Name:Federation Francophone de Cancerologie Digestive
Full Title: MULTICENTER RANDOMIZED PHASE II STUDY COMPARING THE EFFECTIVENESS AND TOLERANCE OF AVELUMAB VERSUS STANDARD 2nd LINE TREATMENT CHEMOTHERAPY IN PATIENTS WITH COLORECTAL METASTATIC CANCER WITH MICROS...
Medical condition: COLORECTAL METASTATIC CANCER WITH MICROSATELLITE INSTABILITY (MSI)
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: FR (Trial now transitioned)
Trial results: (No results available)

EudraCT Number: 2020-002932-64

Sponsor Protocol Number: APHP200133

Start Date*: 2021-07-23

Sponsor Name:Assistance Publique - Hôpitaux de Paris (AP-HP)

Full Title: Prospective randomIzed clinical trial assessing the tolerance and clinical benefit of feCAl tranSplantation in patientS with melanOma treated with CTLA-4 and PD1 inhibitors

Medical condition: melonoma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.1	100000004864	10053571	Melanoma	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2019-001849-41

Sponsor Protocol Number: 69HCL17_0706

Start Date*: 2019-09-06

Sponsor Name:Hospices Civils de Lyon

Full Title: Efficacité de l’éverolimuS pour le traitement des TrAnsplantés Rénaux présentant un Rejet secondaire à l’activation des NK par le « missing-self » - STARR

Medical condition: Patients transplantés rénaux devant avoir une biopsie du greffon rénal dans le cadre du suivi habituel

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	10042613 - Surgical and medical procedures	10038533	Renal transplant	PT

Population Age: Adults

Gender: Male, Female

Trial protocol: FR (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2017-001267-21

Sponsor Protocol Number: BO39610

Start Date*: 2018-01-25

Sponsor Name:F. Hoffman-La Roche Ltd.

Full Title: A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH METASTATIC NONSMALL CEL...

Medical condition: Metastatic non-small cell lung cancer (NSCLC)

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029522	Non-small cell lung cancer stage IV	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) FR (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2016-000808-28

Sponsor Protocol Number: 2015-01

Start Date*: 2016-06-29

Sponsor Name:Centre Oscar Lambret

Full Title: Risk of infertility related to adjuvant chemotherapy in young breast cancer patients: Oocyte/embryo cryopreservation

Medical condition:

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	100000004864	10006188	Breast cancer female NOS	LLT

Population Age: Adults

Gender: Female

Trial protocol: FR (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2022-002319-43	Sponsor Protocol Number: APHP200020	Start Date*: 2022-11-17
Sponsor Name:Assistance Publique - Hôpitaux de Paris
Full Title: Efficacy of 7 days versus 14 days of antibiotic therapy for acute pyelonephritis in kidney transplant recipients, a multicentre randomized non-inferiority trial.
Medical condition: Kidney Transplant recipient with acute pyelonephritis
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: FR (Trial now transitioned)
Trial results: (No results available)

EudraCT Number: 2022-003743-10

Sponsor Protocol Number: BPL-003-201

Start Date*: 2023-06-22

Sponsor Name:Beckley Psytech Ltd.

Full Title: A Quadruple Masked, Dose-Finding Study to Evaluate the Efficacy and Safety of Intranasal BPL-003, with Open Label Extension, in Patients with Treatment Resistant Depression

Medical condition: Treatment-Resistant Depression (TRD)

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.1	10037175 - Psychiatric disorders	10057840	Major depression	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing)

Trial results: (No results available)

EudraCT Number: 2015-001394-41	Sponsor Protocol Number: 00170	Start Date*: 2015-06-10
Sponsor Name:Raimo Tuuminen
Full Title: Predictability of response of aflibercept treatment for wet age-related macular degeneration under the treat-and-moderate extend regimen (TMER) treatment model
Medical condition: Wet age-related macular degeneration
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: FI (Completed)
Trial results: (No results available)

EudraCT Number: 2015-003296-30	Sponsor Protocol Number: 00172	Start Date*: 2015-11-11
Sponsor Name:Raimo Tuuminen
Full Title: Efficacy of steroid and nonsteroidal anti-inflammatory eye drops in management of post-operative inflammation and prevention of pseudophakic cystic macular edema after uncomplicated cataract surgery
Medical condition: Cataract senilis
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: FI (Completed)
Trial results: (No results available)

EudraCT Number: 2013-001245-14

Sponsor Protocol Number: CC-5013-NHL-007

Start Date*: 2013-12-13

Sponsor Name:Celgene Corporation

Full Title: A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Placebo in Subjects With Relapsed/Refractory Indolent Lym...

Medical condition: Relapsed/refractory indolent lymphoma

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	100000004864	10060707	MALT lymphoma	LLT
	20.0	100000004851	10041650	Splenic marginal zone lymphomas	HLT
	20.0	100000004851	10029461	Nodal marginal zone B-cell lymphomas	HLT
	20.0	100000004851	10016903	Follicle centre lymphomas, follicular grade I, II, III	HLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) CZ (Completed) IT (Completed) PT (Completed) ES (Completed) PL (Completed)

Trial results: View results

Subscribe to this Search
To subscribe to the RSS feed for this search click here

. This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.

Download Options:
Number of Trials to download:

Download Content:

Download Format:


Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.

Query did not match any studies.

For support, Contact us.

The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

European Medicines Agency © 1995-Wed Feb 11 06:05:03 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Outside EU/EEA